14 November 2024
Clifford Chance advises Heilpflanzenwohl AG on its acquisition of two OTC products from Haleon
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Gunnar Sachs Lead | Clifford Chance | Partner | Corporate/Healthcare | Düsseldorf |
| Stefan Richter | Clifford Chance | Partner | IP | Düsseldorf |
| Carolin Kemmner | Clifford Chance | Counsel | Corporate/Healthcare | Düsseldorf |
| Alison Evans | Clifford Chance | Counsel | Corporate/Healthcare | Düsseldorf |
| Caroline Giesen | Clifford Chance | Senior associate | Corporate/Healthcare | Düsseldorf |
| Annabel Joschko | Clifford Chance | Associate | Corporate/Healthcare | Düsseldorf |
| Gareth Camp | Clifford Chance | Partner | Corporate | London |
| Stephen Reese | Clifford Chance | Partner | Corporate | London |
| Niall O'Shea | Clifford Chance | Senior associate | Corporate | London |
| Alex Walker | Clifford Chance | Senior associate | Corporate | London |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Heilpflanzenwohl AGBuy-side
- Counterparties
- Haleon Sarl (Sell-side)
Haleon UK IP Limited (Sell-side)